Pierre Gholam, MD

Articles by Pierre Gholam, MD

Dr Gholam on Camrelizumab Plus Rivoceranib in Unresectable HCC

December 11th 2023

Pierre Gholam, MD, discusses findings from the phase 3 CARES-310 trial of camrelizumab plus rivoceranib in patients with unresectable hepatocellular carcinoma.

Closing Thoughts on Advanced HCC and Highlights from ASCO GI 2023

ByMichael A. Morse, MD,Nicole Rich, MD,Pierre Gholam, MD,Daneng Li, MD,Arndt Vogel, MD

April 10th 2023

Closing out this discussion, experts share their final thoughts on advanced HCC treatments and key data presented at the 2023 ASCO Gastrointestinal Cancers Symposium.

Management of Child-Pugh B Patients with Advanced HCC

ByMichael A. Morse, MD,Nicole Rich, MD,Pierre Gholam, MD,Daneng Li, MD,Arndt Vogel, MD

April 3rd 2023

Oncologists provide an overview of the treatment management of Child-Pugh B patients with advanced HCC.

Treatment Considerations for Advanced HCC in Second Line and Beyond

ByMichael A. Morse, MD,Nicole Rich, MD,Pierre Gholam, MD,Daneng Li, MD,Arndt Vogel, MD

April 3rd 2023

In this discussion, panelists outline treatment considerations for patients with advanced HCC in the 2L setting and beyond.

Systemic Immunotherapies for Advanced HCC in Second Line and Beyond

ByMichael A. Morse, MD,Nicole Rich, MD,Pierre Gholam, MD,Daneng Li, MD,Arndt Vogel, MD

March 27th 2023

In the context of frontline treatment strategies in advanced HCC, expert oncologists review clinical research in systemic immunotherapy approaches.

Anti-Angiogenic Systemic Therapies for Advanced HCC in Second Line and Beyond

ByMichael A. Morse, MD,Nicole Rich, MD,Pierre Gholam, MD,Daneng Li, MD,Arndt Vogel, MD

March 27th 2023

Expert panelists highlight anti-angiogenic systemic therapies under investigation for advanced HCC in second line and beyond.

Patient Profile 3: Advanced HCC Treatment in Second Line and Beyond

ByMichael A. Morse, MD,Nicole Rich, MD,Pierre Gholam, MD,Daneng Li, MD,Arndt Vogel, MD

March 20th 2023

Oncologists review a patient profile, evaluating treatment approaches for patients with advanced HCC that have progressed beyond 1L treatment.

Treatment Selection in Patients Unsuitable for Atezolizumab + Bevacizumab

ByMichael A. Morse, MD,Nicole Rich, MD,Pierre Gholam, MD,Daneng Li, MD,Arndt Vogel, MD

March 20th 2023

Experts discuss treatment options for patients unsuitable for atezolizumab plus bevacizumab in advanced hepatocellular carcinoma.

Real-World Evidence for Lenvatinib in Advanced HCC

ByMichael A. Morse, MD,Nicole Rich, MD,Pierre Gholam, MD,Daneng Li, MD,Arndt Vogel, MD

March 13th 2023

Panelists share real-world evidence involving the use of lenvatinib in advanced HCC.

Patient Profile 2: Advanced HCC Treated with Lenvatinib

ByMichael A. Morse, MD,Nicole Rich, MD,Pierre Gholam, MD,Daneng Li, MD,Arndt Vogel, MD

March 13th 2023

A panel of oncologists review a patient profile, evaluating a patient with advanced HCC treated with lenvatinib.

Other Frontline Immunotherapy-based Combinations in Advanced HCC

ByMichael A. Morse, MD,Nicole Rich, MD,Pierre Gholam, MD,Daneng Li, MD,Arndt Vogel, MD

March 6th 2023

Expert oncologists analyze immunotherapy-based combinations in the frontline setting for patients with hepatocellular carcinoma.

Selecting the Appropriate Frontline Treatment in Advanced HCC

ByMichael A. Morse, MD,Nicole Rich, MD,Pierre Gholam, MD,Daneng Li, MD,Arndt Vogel, MD

March 6th 2023

Experts discuss the factors they take into consideration when selecting the appropriate treatment in advanced HCC.

HIMALAYA Study: Durvalumab + Tremelimumab in First-Line Treatment of Advanced HCC

ByMichael A. Morse, MD,Nicole Rich, MD,Pierre Gholam, MD,Daneng Li, MD,Arndt Vogel, MD

February 20th 2023

Panelists review the HIMALAYA study, investigating durvalumab plus tremelimumab in patients with advanced HCC.

Patient Profile 1: Advanced HCC Treated with Durvalumab + Tremelimumab

ByMichael A. Morse, MD,Nicole Rich, MD,Pierre Gholam, MD,Daneng Li, MD,Arndt Vogel, MD

February 20th 2023

Expert oncologists discuss a patient profile in advanced HCC, evaluating a patient treated with durvalumab plus tremelimumab.

Patients With Intermediate Stage HCC Suitable for TACE

ByMichael A. Morse, MD,Nicole Rich, MD,Pierre Gholam, MD,Daneng Li, MD,Arndt Vogel, MD

February 20th 2023

Experts review clinical studies evaluating TACE in patients with intermediate stage HCC.

Patients With Intermediate Stage HCC Unsuitable for TACE

ByMichael A. Morse, MD,Nicole Rich, MD,Pierre Gholam, MD,Daneng Li, MD,Arndt Vogel, MD

February 20th 2023

Expert panelists discuss treatment strategies for patients with intermediate stage hepatocellular carcinoma (HCC) that are unsuitable for transarterial chemoembolization (TACE).

The Evolving Treatment Landscape of HCC

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

August 24th 2022

Closing out their discussion on hepatocellular carcinoma, expert panelists consider future directions in care.

Later-Line IO Therapy for Advanced Hepatocellular Carcinoma

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

August 17th 2022

Comprehensive insight on later-line immunotherapy and combination strategies available for patients with advanced hepatocellular carcinoma.

Selecting Therapy for Advanced HCC Following Atezo-Bev Failure

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

August 17th 2022

Expert panelists consider which therapy they would use following failure of atezolizumab + bevacizumab in advanced hepatocellular carcinoma.

Selecting Therapy for Advanced HCC Following TKI Failure

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

August 10th 2022

Shared insight on which factors help to inform selection of second-line therapy for patients with advanced HCC following lenvatinib failure.

Patient Profile 3: Second-Line Therapy for Advanced HCC

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

August 10th 2022

Centering discussion on a patient with advanced HCC, expert oncologists consider which agents they would use in the second line following lenvatinib failure.

Frontline Therapy for Advanced HCC: Novel Combination Strategies

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

August 3rd 2022

Before closing out their discussion on frontline therapy for advanced HCC, expert panelists review other novel combinations under investigation.

Frontline Lenvatinib versus Sorafenib Treatment in Advanced HCC

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

August 3rd 2022

Comprehensive insight on the selection and use of frontline tyrosine kinase inhibitors for patients with advanced hepatocellular carcinoma.

Role of Hepatitis Status in Selecting Therapy for HCC

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

July 27th 2022

Expert panelists briefly review how a patient’s hepatitis status may influence treatment selection for advanced hepatocellular carcinoma.

Real-World Selection of Frontline Combination Therapy for Advanced HCC

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

July 27th 2022

Taking into account respective data from IMbrave150 and HIMALAYA, experts consider how they might select frontline therapy for advanced HCC.

HIMALAYA: Frontline Durvalumab + Tremelimumab in Advanced HCC

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

July 20th 2022

Shared insight on combination durvalumab + tremelimumab as frontline therapy for advanced HCC in the context of data from the HIMALAYA trial.

Patient Profile 2: Frontline Therapy for Advanced HCC

ByTanios S. Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

July 20th 2022

Centering discussion on a patient with advanced-stage HCC, expert panelists discuss the frontline use of atezolizumab + bevacizumab as a standard of care.